Jackson S.E. Chester J.D.

Personalised cancer medicine.

Int J Cancer. 137: 262-266Coit D.G. Thompson J.A. Albertini M.R. Barker C. Carson W.E. Contreras C. Daniels G.A. DiMaio D. Fields R.C. Fleming M.D. Freeman M. Galan A. Gastman B. Guild V. Johnson D. Joseph R.W. Lange J.R. Nath S. Olszanski A.J. Ott P. Gupta A.P. Ross M.I. Salama A.K. Skitzki J. Sosman J. Swetter S.M. Tanabe K.K. Wuthrick E. McMillian N.R. Engh A.M.

Cutaneous melanoma, version 2.2019.

JNCCN J Natl Compr Cancer Netw. 17: 367-402Costa R. Carneiro B.A. Taxter T. Tavora F.A. Kalyan A. Pai S.A. Chae Y.K. Giles F.J.

FGFR3-TACC3 fusion in solid tumors: mini review.

Oncotarget. 5Lee Y.T. Tan Y.J. Oon C.E.

Molecular targeted therapy: Treating cancer with specificity.

Eur J Pharmacol. 834: 188-196Frampton G.M. Fichtenholtz A. Otto G.A. Wang K. Downing S.R. He J. et al.

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Nat Biotechnol. 31: 1023-1031Cheng D.T. Mitchell T.N. Zehir A. Shah R.H. Benayed R. Syed A. Chandramohan R. Liu Z.Y. Won H.H. Scott S.N. Rose Brannon A. O’Reilly C. Sadowska J. Casanova J. Yannes A. Hechtman J.F. Yao J. Song W. Ross D.S. Oultache A. Dogan S. Borsu L. Hameed M. Nafa K. Arcila M.E. Ladanyi M. Berger M.F.

Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.

J Mol Diagnostics. 17: 251-264Pritchard C.C. Salipante S.J. Koehler K. Smith C. Scroggins S. Wood B. Wu D. Lee M.K. Dintzis S. Adey A. Liu Y. Eaton K.D. Martins R. Stricker K. Margolin K.A. Hoffman N. Churpek J.E. Tait J.F. King M.-C. Walsh T.

Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens.

J Mol Diagnostics. 16: 56-67Zheng Z. Liebers M. Zhelyazkova B. Cao Y. Panditi D. Lynch K.D. Chen J. Robinson H.E. Shim H.S. Chmielecki J. Pao W. Engelman J.A. Iafrate A.J. Le L.P.

Anchored multiplex PCR for targeted next-generation sequencing.

Nat Med. 20: 1479-1484

Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet.

Npj Genomic Med. 1: 15006Kurian A.W. Hare E.E. Mills M.A. Kingham K.E. McPherson L. Whittemore A.S. McGuire V. Ladabaum U. Kobayashi Y. Lincoln S.E. Cargill M. Ford J.M.

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

J Clin Oncol. 32: 2001-2009

Advances in the use of PARP inhibitor therapy for breast cancer.

Drugs Context. 7: 1-30

PARP inhibitors: Synthetic lethality in the clinic.

Science. 355: 1152-1158Bosdet I.E. Docking T.R. Butterfield Y.S. Mungall A.J. Zeng T. Coope R.J. Yorida E. Chow K. Bala M. Young S.S. Hirst M. Birol I. Moore R.A. Jones S.J. Marra M.A. Holt R. Karsan A.

A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.

J Mol Diagnostics. 15: 796-809Cragun D. Radford C. Dolinsky J. Caldwell M. Chao E. Pal T.

Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory.

Clin Genet. 86: 510-520Childers C.P. Childers K.K. Maggard-Gibbons M. Macinko J.

National estimates of genetic testing in women with a history of breast or ovarian cancer.

J Clin Oncol. 35: 3800-3806Seifert B.A. O’Daniel J.M. Amin K. Marchuk D.S. Patel N.M. Parker J.S. Hoyle A.P. Mose L.E. Marron A. Hayward M.C. Bizon C. Wilhelmsen K.C. Evans J.P. Earp H.S. Sharpless N.E. Hayes D.N. Berg J.S.

Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

Clin Cancer Res. 22: 4087-4094Mandelker D. Zhang L. Kemel Y. Stadler Z.K. Joseph V. Zehir A. et al.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

JAMA. 318: 825DeLeonardis K. Hogan L. Cannistra S.A. Rangachari D. Tung N.

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?.

J Oncol Pract. 15: 465-473Raymond V.M. Gray S.W. Roychowdhury S. Joffe S. Chinnaiyan A.M. Parsons D.W. Plon S.E.

Germline findings in tumor-only sequencing: Points to consider for clinicians and laboratories.

J Natl Cancer Inst. 108: 1-5Robson M.E. Bradbury A.R. Arun B. Domchek S.M. Ford J.M. Hampel H.L. Lipkin S.M. Syngal S. Wollins D.S. Lindor N.M.

American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility.

J Clin Oncol. 33: 3660-3667Stjepanovic N. Stockley T.L. Bedard P.L. McCuaig J.M. Aronson M. Holter S. Semotiuk K. Leighl N.B. Jang R. Krzyzanowska M.K. Oza A.M. Gupta A. Elser C. Ahmed L. Wang L. Kamel-Reid S. Siu L.L. Kim R.H.

Additional germline findings from a tumor profiling program.

BMC Med Genomics. 11: 1-8

The emerging significance of secondary germline testing in cancer genomics.

J Pathol. 244: 610-615

Liang JC, Ning Y, Wang R yu, Padilla-Nash HM, Schröck E, Soenksen D, Nagarajan L, Ried T. Spectral karyotypic study of the HL-60 cell line: Detection of complex rearrangements involving chromosomes 5, 7, and 16 and delineation of critical region of deletion on 5q31.1. Cancer Genet Cytogenet, 1999, 113:105–109

Leroy B. Girard L. Hollestelle A. Minna J.D. Gazdar A.F. Soussi T.

Analysis of TP53 mutation status in human cancer cell lines: A reassessment.

Hum Mutat. 35: 756-765Moore R.A. Zeng T. Docking T.R. Bosdet I. Butterfield Y.S. Munro S. Li I. Swanson L. Starks E.R. Tse K. Mungall A.J. Holt R.A. Karsan A.

Sample Tracking Using Unique Sequence Controls.

J Mol Diagnostics. 22: 141-146Chen S. Zhou Y. Chen Y. Gu J.

Fastp: An ultra-fast all-in-one FASTQ preprocessor.

Bioinformatics. 34: i884—-i890

Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM, ArXiv, 2013, 00:1–3

Biobambam: Tools for read pair collation based algorithms on BAM files.

Source Code Biol Med. 9: 1-18Li H. Handsaker B. Wysoker A. Fennell T. Ruan J. Homer N. Marth G. Abecasis G. Durbin R.

The Sequence Alignment/Map format and SAMtools.

Bioinformatics. 25: 2078-2079Koboldt D.C. Zhang Q. Larson D.E. Shen D. McLellan M.D. Lin L. Miller C.A. Mardis E.R. Ding L. Wilson R.K.

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Genome Res. 22: 568-576Ogino S. Gulley M.L. Dunnen JT den Wilson R.B. Payne D. Lowery Nordberg M.C. Gong J.Z. Krafft A.E. Uphoff T.S. Donahue P. Hunt J. Garrison G.

Standard mutation nomeclature in molecular diagnostics: Practical and educational challenges.

J Mol Diagnostics. 9: 1-6Boeva V. Popova T. Lienard M. Toffoli S. Kamal M. Le Tourneau C. Gentien D. Servant N. Gestraud P. Rio Frio T. Hupé P. Barillot E. Laes J.-F.

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.

Bioinformatics. 30: 3443-3450

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 581:434-443.

Win A.K. Reece J.C. Dowty J.G. Buchanan D.D. Clendenning M. Rosty C. Southey M.C. Young J.P. Cleary S.P. Kim H. Cotterchio M. Macrae F.A. Tucker K.M. Baron J.A. Burnett T. Le Marchand L. Casey G. Haile R.W. Newcomb P.A. Thibodeau S.N. Hopper J.L. Gallinger S. Winship I.M. Lindor N.M. Jenkins M.A.

Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.

Int J Cancer. 139: 1557-1563Robinson J.T. Thorvaldsdóttir H. Winckler W. Guttman M. Lander E.S. Getz G. Mesirov J.P.

Integrative genomics viewer.

Nat Biotechnol. 29: 24-26Zook J.M. Chapman B. Wang J. Mittelman D. Hofmann O. Hide W. Salit M.

Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls.

Nat Biotechnol. 32: 246-251Drmanac R. Sparks A.B. Callow M.J. Halpern A.L. Burns N.L. Kermani B.G. et al.

Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays.

Science. 327: 78-81Li M.M. Datto M. Duncavage E.J. Kulkarni S. Lindeman N.I. Roy S. Tsimberidou A.M. Vnencak-Jones C.L. Wolff D.J. Younes A. Nikiforova M.N.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

J Mol Diagnostics. 19: 4-23Kivioja T. Vähärautio A. Karlsson K. Bonke M. Enge M. Linnarsson S. Taipale J.

Counting absolute numbers of molecules using unique molecular identifiers.

Nat Methods. 9: 72-74Mandelker D. Donoghue M. Talukdar S. Bandlamudi C. Srinivasan P. Vivek M. Jezdic S. Hanson H. Snape K. Kulkarni A. Hawkes L. Douillard J.Y. Wallace S.E. Rial-Sebbag E. Meric-Bersntam F. George A. Chubb D. Loveday C. Ladanyi M. Berger M.F. Taylor B.S. Turnbull C.

Germline-focussed analysis of tumour-only sequencing: Recommendations from the ESMO Precision Medicine Working Group.

Ann Oncol. 30: 1221-1231Maxwell K.N. Wubbenhorst B. Wenz B.M. De Sloover D. Pluta J. Emery L. Barrett A. Kraya A.A. Anastopoulos I.N. Yu S. Jiang Y. Chen H. Zhang N.R. Hackman N. D’Andrea K. Daber R. Morrissette J.J. Mitra N. Feldman M. Domchek S.M. Nathanson K.L.

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.

Nat Commun. 8Jones S. Anagnostou V. Lytle K. Parpart-Li S. Nesselbush M. Riley D.R. Shukla M. Chesnick B. Kadan M. Papp E. Galens K.G. Murphy D. Zhang T. Kann L. Sausen M. Angiuoli S.V. Diaz L.A. Velculescu V.E.

Personalized genomic analyses for cancer mutation discovery and interpretation.

Sci Transl Med. 7 ()Samadder N.J. Riegert-Johnson D. Boardman L. Rhodes D. Wick M. Okuno S. Kunze K.L. Golafshar M. Uson P.L.S. Mountjoy L. Ertz-Archambault N. Patel N. Rodriguez E.A. Lizaola-Mayo B. Lehrer M. Thorpe C.S. Yu N.Y. Esplin E.D. Nussbaum R.L. Sharp R.R. Azevedo C. Klint M. Hager M. MacKlin-Mantia S. Bryce A.H. Bekaii-Saab T.S. Sekulic A. Stewart A.K.

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients with Hereditary Cancer Syndrome.

JAMA Oncol. 7: 230-237